Aquatic Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.56M Sell
75,708
-4,137
-5% -$88.3K 0.05% 460
2026
Q2
$1.47M Buy
79,845
+11,384
+17% +$183K 0.05% 454
2026
Q1
$1.34M Buy
68,461
+43,997
+180% +$1.31M 0.04% 485
2025
Q4
$761K Buy
+24,464
New +$671K 0.02% 615

Other funds holding VRDN

Aquatic Capital Management's VRDN Position: Q3 2026 in Review

Aquatic Capital Management reduced its Viridian Therapeutics (VRDN) stake by 5.2% in Q3 2026, selling an estimated $88.3K and leaving 75,708 shares worth $1.56M. The position accounts for 0.05% of the portfolio, ranked #460.

Aquatic Capital Management first reported a position in VRDN in Q4 2025 and has held it in 4 quarters since. 235 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.

  • Aquatic Capital Management held 75,708 shares of Viridian Therapeutics worth $1.56M as of Q3 2026.
  • Aquatic Capital Management sold 4,137 Viridian Therapeutics shares in Q3 2026, an estimated $88.3K.
  • Viridian Therapeutics made up 0.05% of Aquatic Capital Management's portfolio in Q3 2026, its #460 holding.
  • Aquatic Capital Management first reported a position in Viridian Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • 235 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.

Based on Aquatic Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.